GlassScriptPhysician profile
Miu K Ma
NPI 1205890175
$1,270.25
in general payments reported to CMS, 2019-2025
10 companies · $96.29 in 2025
The $96.29 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $29.79 · 2021: $23.56 · 2022: $286 · 2023: $69.67 · 2024: $63.89 · 2025: $96.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $594.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $259.30 | 2019-2025 | Bexsero, Penmenvy, Boostrix |
| Seqirus USA INC | $106.22 | 2019-2025 | Flucelvax, Fluad |
| Janssen Pharmaceuticals, INC | $80.00 | 2019 | |
| Kaleo, INC. | $55.07 | 2022 | |
| Pfizer INC. | $46.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $33.42 | 2019 | |
| Alk-Abello, INC | $25.05 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $24.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miu Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.